Search Results

Abbott Vascular's XIENCE 28 GLOBAL Trial Enrolls First Patient in Europe

February 12, 2018—Abbott Vascular announced the first patient has been enrolled in XIENCE 28 GLOBAL, a clinical trial evaluating whether patients at high risk of bleeding can safely remain on dual antiplatelet therapy (DAPT) for only 28 days after implantation with a Xience everolimus-eluting coronary stent.

Twelve-Month e-HEALING Data Published for OrbusNeich's Genous Stent

February 22, 2011—OrbusNeich (Fort Lauderdale, FL) announced that 12-month follow-up data from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) demonstrated good clinical outcomes with low incidence of repeat revascularization and stent thrombosis for the company's Genous stent.

ReCor Medical Paradise uRDN System Evaluated in Concurrently Published RADIANCE Studies

February 28, 2023—ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd., announced the publication of primary endpoint results from the RADIANCE II pivotal trial, which showed that the Paradise ultrasound renal denervation (uRDN) system successfully reduced blood pressure compared to a sham control.